种属反应性
human
包装
kit of 96 wells (12 strips x 8 wells)
技术
ELISA: suitable
输入
sample type serum
sample type cell culture supernatant(s)
sample type plasma
assay range
inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 48 pg/mL
standard curve range: 0.049-12 ng/mL
检测方法
colorimetric
运输
wet ice
储存温度
−20°C
基因信息
human ... TNFRSF17(608)
一般描述
The antibody pair provided in this kit recognizes human Tumor Necrosis Factor Receptor Superfamily Member 17.
应用
请参考Protocol了解详情。
警示用语:
Warning
危险声明
预防措施声明
危险分类
Met. Corr. 1
储存分类代码
8A - Combustible corrosive hazardous materials
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Gene therapy, 26(5), 187-197 (2019-03-31)
Patients with immunoglobulin (Ig) light-chain (LC) diseases such as LC light-chain amyloidosis die with organ failure and need new therapies. We sought a model to test anti-LC siRNA delivery to human plasma cells, requiring circulating LC, in vivo indicators of
Frontiers in immunology, 9, 2351-2351 (2018-10-30)
Introduction: B-cell activation is pivotal in rheumatoid arthritis (RA) pathogenesis and represents a relevant therapeutic target. The main aim of this study was to characterize the profiles of B-cell factors and their decoy receptors in RA and evaluate their clinical
Journal of immunology (Baltimore, Md. : 1950), 198(8), 3081-3088 (2017-03-12)
The BAFF-APRIL system is best known for its control of B cell homeostasis, and it is a target of therapeutic intervention in autoimmune diseases and lymphoma. By analyzing the expression of the three receptors of this system, B cell maturation
Molecular cancer therapeutics, 20(2), 367-378 (2020-12-11)
Despite major treatment advances in recent years, patients with multiple myeloma inevitably relapse. The RNA polymerase II complex has been identified as a promising therapeutic target in both proliferating and dormant cancer cells. Alpha-amanitin, a toxin so far without clinical
Leukemia, 35(3), 752-763 (2020-07-08)
Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门